{"rows":[{"id":1769,"title":"The therapeutic potential of psilocybin: a systematic review.","authors":"van Amsterdam J, van den Brink W","journal":"Expert opinion on drug safety","publication_date":"2022-06-01","publication_year":2022,"doi":"10.1080/14740338.2022.2047929","pubmed_id":"35225143","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/35225143/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:20","bibtex":null,"source_record_id":"PMID:35225143","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/35225143/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:35225143","source_url":"https://pubmed.ncbi.nlm.nih.gov/35225143/","doi":"10.1080/14740338.2022.2047929","pmid":"35225143","publication_date":"2022-06-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1762,"title":"Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?","authors":"Husain MI, Umer M, Mulsant BH","journal":"Expert opinion on drug safety","publication_date":"2022-06-01","publication_year":2022,"doi":"10.1080/14740338.2022.2063274","pubmed_id":"35387542","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/35387542/","substance_tags":"psilocybin","topic_tags":"Depression,PTSD,Addiction,Safety","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:20","bibtex":null,"source_record_id":"PMID:35387542","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:35387542","source_url":"https://pubmed.ncbi.nlm.nih.gov/35387542/","doi":"10.1080/14740338.2022.2063274","pmid":"35387542","publication_date":"2022-06-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1761,"title":"Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.","authors":"Rossi GN, Hallak JEC, Bouso Saiz JC, Dos Santos RG","journal":"Expert opinion on drug safety","publication_date":"2022-06-01","publication_year":2022,"doi":"10.1080/14740338.2022.2066650","pubmed_id":"35426754","openalex_id":"https://openalex.org/W4223893856","source_url":"https://pubmed.ncbi.nlm.nih.gov/35426754/","substance_tags":"psilocybin","topic_tags":"Depression,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:20","bibtex":null,"source_record_id":"PMID:35426754","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/35426754/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:35426754","source_url":"https://pubmed.ncbi.nlm.nih.gov/35426754/","doi":"10.1080/14740338.2022.2066650","pmid":"35426754","publication_date":"2022-06-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1437,"title":"Serotonin 5-HT receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents.","authors":"McIntyre RS","journal":"Expert opinion on drug safety","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1080/14740338.2023.2248883","pubmed_id":"37581427","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/37581427/","substance_tags":"psilocybin","topic_tags":"Receptor Pharmacology","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:14","bibtex":null,"source_record_id":"PMID:37581427","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37581427","source_url":"https://pubmed.ncbi.nlm.nih.gov/37581427/","doi":"10.1080/14740338.2023.2248883","pmid":"37581427","publication_date":"2023-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1436,"title":"Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.","authors":"McIntyre RS","journal":"Expert opinion on drug safety","publication_date":"2023-01-01","publication_year":2023,"doi":"10.1080/14740338.2023.2253144","pubmed_id":"37635320","openalex_id":"https://openalex.org/W4386209201","source_url":"https://pubmed.ncbi.nlm.nih.gov/37635320/","substance_tags":"psilocybin","topic_tags":"Pharmacology","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:14","bibtex":null,"source_record_id":"PMID:37635320","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/37635320/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37635320","source_url":"https://pubmed.ncbi.nlm.nih.gov/37635320/","doi":"10.1080/14740338.2023.2253144","pmid":"37635320","publication_date":"2023-01-01","importer_version":"2.1.3","text_redistributed":false}}],"total":5,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Expert opinion on drug safety","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}